News | April 28, 2022
Sanofi continues to deliver strong business
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
Business EPS of €1.94, up 20.5% on a reported basis and 16.1% at CER, also benefitting from an improved effective tax rate
When a critical patient is en-route to the hospital and every second makes a difference, the 5G Connected ambulance acts as an extension of the emergency room
These bulk orders will contribute to the topline of the company as well as help in improving EBITDA of the company
Star Array's focus has been on the development of an automated (cassette-based) nucleic acid purification system coupled with its superfast nucleic acid amplification technology
Beyond the technical leadership from F1, the collaboration will bring a specific focus on the people dimension of high performance
Recognition illustrates Takeda’s patient-centricity throughout its manufacturing and supply processes
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Revenue from operations up 15% to Rs. 758 crore in fourth quarter
The minister was speaking at the 7th International conference on Pharma and Medical Devices sector; chairs two roundtable conferences with the CEOs
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Subscribe To Our Newsletter & Stay Updated
